Table 3.
Current status of anti-sepsis agents in clinical trials
| S. No. | Drug | Company | Mechanism | Phase/Comments |
|---|---|---|---|---|
| 1 | Toraymyxin | Spectral Diagnostics | Removes endotoxin | IIIb |
| 2 | Alkaline phosphatase | AM-Pharma | Detoxifies bacterial Products | II |
| 4 | Eritoran (E5564) | Eisai | Antagonizes TLR4 | III; failed to reduce 28 day and 1 year sepsis-induced mortality |
| 5 | Lactoferrin-α | Agennix | Immunomodulatory and Antibacterial properties | II/IIIa |
| 6 | CytoFab (AZD9773) | Astra Zeneca | Fab fragments of IgG that bind to TNF-α | II; further clinical development has been stopped |
| 7 | Resatorvid (TAK 242) | Takeda | Antagonize TLR4 | III; further clinical development has been stopped |
| 8 | SRT2379 | GlaxoSmithKline | Sirtuin-1 activator | I |
| 9 | Bicizar | BioGenius | C1-esterase inhibitor blocks complement activation | III |
| 10 | Citrulline | Vanderbilt University | Precursor of NO | II |
| 11 | Hydrocortisone | Charite University, Berlin, Germany | Alters cytokine response | III |
| 12 | Recombinant human soluble thrombomodulin (ART-123) | Artisan Pharma, Inc. | Binds to thrombin | II |
| 13 | Anti-TF mAbs (ALT-836) | Altor Bioscience Corporation | Blocks TF induced inflammation | II |
| 14 | Atorvastatin | Hospital de Clinicas de Porto Alegre | Suppression of the TLR-dependent inflammatory pathway | II |
Data were obtained from http://www.clinicaltrials.gov (as of 22 October 2012).
a
The OASIS trial of talactoferrin alfa should be completed by 2014.
b
EUPHRATES trial of endotoxin removal by haemoperfusion through a polymyxin B column is scheduled for completion in 2013 (The Lancet Infectious Diseases, 2012).